Kadin D V, Chumak B A, Filippov A E, Shustov S B
Kardiologiia. 2015;55(8):26-9.
Trimetazidine is a metabolic agent of proven efficacy in improving myocardial ischemia and angina. A comparative international multicenter randomized trial, assessed anti-anginal anti ischemic efficacy and safety of Trimetazidine (60 mg/d) and Thiotriazoline (600 mg/d) in symptomatic patients with chronic ischemic heart disease receiving the first line therapy. The study assessed the efficacy of the two drugs on total exercise duration, time to 1-mm ST segment depression, the number of angina attacks and nitroglycerin tablets consumed amount. Both drugs have demonstrated clinical efficacy equal for all primary and secondary endpoints.
曲美他嗪是一种经证实对改善心肌缺血和心绞痛有效的代谢药物。一项比较性国际多中心随机试验，评估了曲美他嗪（60毫克/天）和硫氮卓啉（600毫克/天）在接受一线治疗的慢性缺血性心脏病有症状患者中的抗心绞痛和抗缺血疗效及安全性。该研究评估了两种药物对总运动持续时间、ST段压低1毫米的时间、心绞痛发作次数和硝酸甘油片消耗量的疗效。两种药物在所有主要和次要终点上均显示出同等的临床疗效。
